Product cost becomes key in biotech drug development

04/2/2012 | Xconomy

Drugmakers must consider their products' cost-effectiveness as payer and government budgets tighten, writes Luke Timmerman. Insurers considering antibody-based cholesterol drugs, for example, will want proof that the drugs go beyond simply working better than cheap generic statins, and venture capitalists increasingly consider cost and payer issues. "Reimbursement (which integrates the cost effective issue) is a key issue for us investing in any company, at any stage," says Mike Powell of Sofinnova Ventures.

View Full Article in:

Xconomy

Published in Briefs: